The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | An insight into the standard of care in HR-MDS and future outlooks
In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, shares some insights into the standard of care in high-risk myelodysplastic syndromes (HR-MDS). Dr Sallman first comments on the role of hypomethylating agents (HMAs) such as azacitidine in this population, and further discusses the importance of allogeneic stem cell transplantation (alloSCT) and the growing role of combination approaches. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
